Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F14%3A%230001189" target="_blank" >RIV/00064190:_____/14:#0001189 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1402584" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1402584</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1402584" target="_blank" >10.1056/NEJMoa1402584</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Original language description
Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
The New England journal of medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
370
Issue of the periodical within the volume
22
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
2071-2082
UT code for WoS article
—
EID of the result in the Scopus database
—